30-day average of 22 articles ยท scale โ100 to +100
Across 22 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Intuitive Surgical news is Somewhat Bullish (+37)
on a scale from โ100 to +100.
That is down 7 points from the previous 30 days (+44).
๐ Worldwide procedures grew 14%, with international markets up 20%.
๐ U.S. da Vinci procedure growth slowed to 10% in Q3.
Slightly Bullish +20
A $5.9 Billion Fund Is Betting Big on Intuitive Surgical
AI-generated analysis
Key insights
๐ Intuitive Surgical's U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest level since the COVID-19 pandemic.
๐ Worldwide da Vinci procedures grew 14% in Q3, with international markets expanding at a robust 20% rate.
๐ฐ The company placed 546 da Vinci systems in the third quarter, up from 427 placements a year earlier.
โ๏ธ Intuitive plans to reduce instrument and accessory revenue per procedure by 3% to 5% to win high-volume benign surgeries.
๐ Valuation compression has pushed the stock to 37x forward earnings, down from a five-year average of 54x.
๐ The consensus analyst price target fell from $593 to $487 following recent operational and financial data.
๐ผ GuardCap Asset Management opened a new position in ISRG with 167,863 shares worth $68 million in Q3.
๐ญ Analysts expect normalized EPS to grow from $8.93 in 2025 to $14.04 by 2028.
๐ The next major catalyst is the fourth-quarter report expected early next year regarding U.S. growth trends.
๐ Bullish signals
๐Intuitive Surgical achieved a 22% revenue increase and 14% worldwide procedure growth in Q3, driven by strong international expansion.
๐ฐThe company successfully placed 546 da Vinci systems in the third quarter, demonstrating continued hospital adoption despite domestic headwinds.
๐ญAnalysts project normalized earnings per share to rise significantly from $8.93 in 2025 to $14.04 by 2028.
๐ Risk factors
๐U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest rate seen since the COVID-19 pandemic.
โ๏ธThe company plans to cut instrument and accessory revenue per procedure by 3% to 5%, which will temporarily reduce revenue per case before volume gains materialize.
๐Valuation compression has driven the stock price down to 37x forward earnings, well below its five-year average of 54x.
Article
Intuitive Surgical (ISRG) recently faced headwinds as U.S. da Vinci procedure growth slowed to 10% in the third quarter, marking its lowest rate since the COVID-19 pandemic. Despite this domestic slowdown, the company reported a 22% revenue increase and 14% worldwide procedure growth, driven by strong international expansion with 20% growth outside the U.S. Additionally, Intuitive successfully placed 546 da Vinci systems in the third quarter, an increase from 427 a year prior.
To capture more high-volume benign surgeries, Intuitive Surgical plans to cut instrument and accessory revenue per procedure by 3% to 5%. This strategic pricing adjustment has caused the stock to trade at 37x forward earnings, significantly below its five-year average of 54x. Consequently, the consensus analyst price target has decreased from $593 a year ago to $487, though this still implies potential upside from recent lows.
GuardCap Asset Management, which oversees $5.9 billion in assets, initiated a new position in Intuitive Surgical during the third quarter, purchasing 167,863 shares worth approximately $68 million. This investment represents 4.7% of GuardCap's U.S. stock holdings and is its largest new or added position for the period. Analysts project normalized earnings per share to rise from $8.93 in 2025 to $14.04 by 2028, suggesting long-term growth potential despite current valuation compression.
The company's next critical test will be its fourth-quarter report early next year, which is expected to provide clarity on U.S. procedure growth trends for 2027. Investors are closely watching whether the domestic slowdown persists or if international momentum can offset any further declines in the core U.S. market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Intuitive Surgical (ISRG) is preparing to release its Q3 earnings, with the stock trading at $426, significantly below its 52-week high despite recent institutional buying and a 12% gain over the past month. Analysts expect EPS between $2.61 and $2.65 on revenue of approximately $2.88 billion, representing year-over-year growth of roughly 9% and 15% respectively. The company has successfully beaten these consensus estimates for four consecutive quarters, establishing a strong track record of performance.
Procedure volume remains the primary engine driving Intuitive Surgical's growth, with combined da Vinci and Ion procedures increasing by 17% in Q1 and 16% in Q2. For the first half of the year, revenues climbed approximately 21% to $5.66 billion, fueled largely by the adoption of the latest Da Vinci 5 system, which accounted for 246 of the 468 systems placed in Q2. The global installed base now exceeds 11,700 da Vinci systems, indicating robust market penetration.
International expansion continues to be a key growth vector, particularly for the Ion lung biopsy platform and general surgery procedures outside the United States. While procedure volume growth has outpaced the 13.5% to 15.5% guidance provided for 2026, the stock's high valuation multiple of roughly 49x trailing earnings leaves little room for disappointment. Investors will be closely watching whether Q3 can maintain the 16% procedure growth pace seen in Q2.
Competitive pressures in China and macroeconomic factors like tariffs present ongoing risks to Intuitive Surgical's margins and market share. Management has maintained full-year 2026 non-GAAP gross margin guidance between 68% and 69%, citing tariffs as a persistent factor. With analyst consensus targets near $499, the stock implies roughly 17% upside, but the high valuation requires sustained business momentum to justify the premium.
๐ ISRG Q3 EPS expected between $2.61-$2.65 on $2.88B revenue.
๐ Combined da Vinci and Ion procedures grew 17% in Q1 and 16% in Q2.
๐ง Da Vinci 5 adoption accelerated with 246 systems placed in Q2.
โ ๏ธ ISRG trades at 49x trailing earnings, limiting margin for any miss.
๐จ๐ณ Chinese domestic robotic competitors pose a genuine risk to dominance.
๐ Intuitive Surgical is set to report Q3 earnings with consensus estimates of $2.61-$2.65 EPS and $2.88 billion revenue.
๐ Combined da Vinci and Ion procedures grew 17% in Q1 and 16% in Q2, driving first-half revenues up 21% to $5.66 billion.
๐ง Da Vinci 5 adoption accelerated in Q2 with 246 systems placed, contributing to a global installed base exceeding 11,700 units.
๐ International procedure growth reached 19% in Q1, with Q2 expansion outside the U.S. driven primarily by general surgery.
๐ฐ The Ion lung biopsy platform has expanded into 12 countries outside the United States, diversifying revenue streams.
โ ๏ธ ISRG trades at a premium valuation of roughly 49x trailing earnings, leaving limited margin for any earnings miss.
๐จ๐ณ Competitive pressure from domestic robotic surgery companies in China poses a genuine risk to market dominance.
๐ High macroeconomic vulnerability exists due to the Philadelphia Semiconductor Index's recent worst eight-day streak since 2008.
๐ฏ Key metrics for Q3 include maintaining 16% procedure volume growth and holding gross margin guidance at 68%-69%.
๐ฆ UBS maintains a Buy rating with a $500 target price, while the consensus average across 22 analysts is near $499.
Bullish Signals
Beat earnings for four consecutive quarters.
Risk Factors
Stock trades 29% below $603.88 high.
Valuation at 49x earnings limits upside.
China robotic surgery competition gaining share.
Tariffs add margin uncertainty.
Macro vulnerability from semiconductor index.
Bullish Signals
Intuitive Surgical has beaten earnings estimates for four consecutive quarters, demonstrating consistent execution and market demand.
Combined da Vinci and Ion procedure volumes grew 17% in Q1 and 16% in Q2, validating the core business engine.
First-half revenues rose approximately 21% to $5.66 billion, reflecting strong top-line growth driven by system placements.
The Da Vinci 5 system saw significant adoption with 246 units placed in Q2, up from 180 a year earlier.
International da Vinci procedure growth ran at 19% in Q1, indicating successful global expansion strategies.
The Ion platform has successfully expanded to 12 countries outside the United States, diversifying geographic revenue.
Management maintained full-year 2026 non-GAAP gross margin guidance at 68% to 69%, confirming operating leverage.
Analyst consensus targets near $499 imply roughly 17% upside from current trading levels of $426.
Risk Factors
The stock trades at a deep discount to its 52-week high, sitting 29% below $603.88 despite recent gains.
A valuation premium of roughly 49x trailing earnings leaves limited margin for disappointment in the next report.
Competitive pressure from domestic robotic surgery companies is gaining share in China, a previously unchallenged market.
Tariffs are cited as an ongoing factor impacting margins, adding uncertainty to financial performance.
The Philadelphia Semiconductor Index's recent worst eight-day streak since 2008 adds macroeconomic vulnerability to the stock.
Intuitive Surgical (ISRG) stock is currently trading at US$427.86, reflecting a 56.5% gain over the past three years. The article evaluates whether this valuation remains justified given new competition in the robotic surgery sector, specifically Johnson & Johnson's FDA-cleared OTTAVA system, which could impact Intuitive Surgical's future procedure volumes and pricing power.
A Discounted Cash Flow (DCF) analysis suggests that Intuitive Surgical's current share price is broadly aligned with its intrinsic value. The model projects free cash flow rising from approximately $2.7 billion in the latest twelve months to around $5.9 billion by 2030, assuming growth rates gradually slow as the business matures.
Market sentiment regarding Intuitive Surgical is divided between a bullish view that the company's recurring revenue model and strong moat make it 20% undervalued, and a bearish view that current numbers imply the stock is already fully priced in, potentially making it 32% overvalued with limited room for disappointment.
๐ ISRG stock gained 56.5% over past three years, trading at US$427.86.
โ ๏ธ J&J's OTTAVA system introduces competition affecting ISRG procedure volumes and pricing.
๐ฐ ISRG generated approximately $2.7 billion in free cash flow over latest twelve months.
๐ DCF projections assume ISRG free cash flow will reach roughly $5.9 billion by 2030.
๐ Bull case suggests ISRG is 20% undervalued due to robust recurring revenue model.
๐ Intuitive Surgical stock has gained 56.5% over the past three years, trading at US$427.86.
โ ๏ธ Johnson & Johnson's FDA-cleared OTTAVA system introduces new competition that may affect Intuitive Surgical's future procedure volumes and pricing power.
๐ฐ The company generated approximately $2.7 billion in free cash flow over the latest twelve months.
๐ DCF projections assume Intuitive Surgical's free cash flow will reach roughly $5.9 billion by 2030.
๐ Bull case scenarios suggest Intuitive Surgical is 20% undervalued due to its robust recurring revenue model and strong moat.
๐ป Bear case scenarios indicate the stock may be 32% overvalued as current prices reflect strong growth and high margins.
Bullish Signals
Intuitive Surgical generated $2.7B free cash flow last year.
Robust recurring revenue from instruments, maintenance, and software.
Risk Factors
J&J's FDA-cleared OTTAVA system threatens Intuitive Surgical's future procedure volumes.
New competitor OTTAVA may reduce Intuitive Surgical's pricing power.
Bullish Signals
Intuitive Surgical has generated approximately $2.7 billion in free cash flow over the latest twelve months, demonstrating strong cash generation capabilities.
The company possesses a robust business model characterized by recurring revenue from instrument purchases, maintenance services, and software updates.
Risk Factors
Johnson & Johnson's FDA-cleared OTTAVA system introduces new competition that could negatively impact Intuitive Surgical's future procedure volumes and pricing power.
Intuitive Surgical (ISRG) is maintaining a strong financial trajectory ahead of its third-quarter earnings report scheduled for October 20, 2026. The company recently reported robust second-quarter results with revenue reaching USD 2.89 billion, representing an 18.40% year-over-year increase. Operating margins remained healthy at 34%, while operating cash flow hit USD 1.06 billion for the period ended June 30, 2026.
Analyst sentiment remains positive as UBS maintained its Buy rating and a USD 500 price target on October 13, 2026. The analyst noted that concerns regarding procedure volume appeared overly cautious in their view. However, the report highlighted a potential 4% headwind expected from the Extended Use Program in 2027, providing investors with a specific counter-factor to consider before the upcoming results.
Market consensus estimates for the third quarter project revenue of USD 2.91 billion and earnings per share of USD 2.65. The stock is currently trading at EUR 377.00, slightly above its recent Xetra close. Investors will be watching to see if the projected revenue can extend the impressive growth rate seen in the second quarter.
Intuitive Surgical continues to lead the market with its da Vinci robotic-assisted systems for minimally invasive surgery. The company recently highlighted a meta-analysis covering 13 benign conditions, further expanding its clinical footprint. With the upcoming earnings call on October 20, the market will test whether Intuitive can sustain its momentum amidst potential procedural volume headwinds.
๐ UBS maintains Buy rating with USD 500 price target for ISRG.
๐ฐ Q2 revenue hit USD 2.89 billion, up 18.40% year over year.
Johnson & Johnson reported third-quarter results that beat Wall Street estimates on total revenue but missed expectations for its medical devices segment. The company posted quarterly revenue of US$25.4 billion, surpassing analyst estimates of US$25.28 billion, with adjusted earnings of US$2.59 per share topping expectations by 5 cents. However, the medical technology division specifically underperformed, recording sales of US$8.6 billion against an estimate of US$8.71 billion, marking the second consecutive quarter of misses for this unit.
Chief Financial Officer Joe Wolk attributed the weakness in the medical devices business to geopolitical headwinds, particularly the Middle East conflict, as well as austerity measures in Europe and pricing pressures in China. While fuel costs have not yet impacted the company's bottom line, sales in key markets like Kuwait, UAE, and Saudi Arabia were hurt as these nations reallocated budgets toward defense spending rather than healthcare. The division saw a 2.5% overall rise to US$8.6 billion globally, but sales outside the United States remained essentially flat.
Pharmaceutical sales provided a significant boost to the broader results, jumping 7.7% to US$16.76 billion driven by strong performance in autoimmune treatments like Tremfya and Darzalex. Despite facing generic competition that caused Stelara sales to fall 54%, the drug still exceeded diminished expectations. The company also reaffirmed its plan to spin off its orthopedics unit, DePuy Synthes, aiming for a mid-2027 separation to focus on higher-growth segments and create long-term value for shareholders.
Analysts noted that J&J's specific disruptions from China supply chains and the pending spin-off make it difficult to generalize the medical device miss to the wider sector. While shares fell more than six percent following the report, the company raised its full-year sales forecast to US$101.2 billion and increased its adjusted earnings midpoint to US$11.10 per share, signaling confidence in improving fourth-quarter performance despite current headwinds.
โ ๏ธ J&J missed Q3 sales estimates for second consecutive quarter at $8.6B.
๐ Total Q3 revenue of $25.4B beat Wall Street estimates of $25.28B.
๐ Pharma sales surged 7.7% driven by 68% increase in Tremfya revenue.
๐ Raised full-year adjusted earnings forecast midpoint to $11.10 per share.
โ๏ธ Reaffirmed plan to spin off DePuy Synthes orthopedics unit by mid-2027.
๐ J&J's medical technology division reported Q3 sales of US$8.6 billion, missing analyst estimates of US$8.71 billion for the second consecutive quarter.
๐ Geopolitical tensions in the Middle East and austerity in Europe weighed heavily on international device sales, with key markets like Saudi Arabia shifting budgets to defense.
๐ Pharmaceutical sales surged 7.7% to US$16.76 billion, driven by a 68% increase in Tremfya revenue which now largely replaces lost Stelara income.
๐ The company raised its full-year adjusted earnings forecast midpoint to US$11.10 per share and total sales guidance to US$101.2 billion.
โ๏ธ J&J reaffirmed its plan to spin off the DePuy Synthes orthopedics unit by mid-2027 to sharpen focus on higher-growth healthcare segments.
๐ Total Q3 revenue of US$25.4 billion beat Wall Street estimates of US$25.28 billion, with adjusted earnings topping expectations by 5 cents.
Risk Factors
Medical tech sales missed estimates at $8.6B for second straight quarter.
Bullish Signals
J&J reported third-quarter total revenue of US$25.4 billion, beating analyst estimates of US$25.28 billion.
Pharmaceutical sales jumped 7.7% to US$16.76 billion, with Tremfya revenue rising 68% to US$2.4 billion and exceeding expectations.
The company raised its full-year adjusted earnings forecast midpoint to US$11.10 per share from the previous US$11.04.
J&J increased its full-year sales forecast to US$101.2 billion, indicating confidence in improving fourth-quarter performance.
Sales of Darzalex rose 16% to US$4.24 billion, demonstrating continued strength in the blood cancer treatment portfolio.
Risk Factors
Medical technology division sales fell short of estimates at US$8.6 billion against expectations of US$8.71 billion for the second straight quarter.
International device sales were flat outside the US due to geopolitical issues in the Middle East and austerity measures in Europe.
Pricing pressures in China continued to weigh on results, contributing to the underperformance in the medical devices segment.
Shares fell more than six percent following the earnings report as investors reacted to the weak medical device sales.
Intuitive Surgical stock traded at EUR 378.93 on October 10, 2026, representing a marginal 0.02 percent increase from the previous Xetra close of EUR 378.85. Weekend trading activity at Lang & Schwarz showed prices ranging between EUR 360.28 and the session high of EUR 378.93, with the market anticipating the next trading session scheduled for October 12, 2026.
Zacks Research published a report on October 6, 2026, highlighting significant growth in Intuitive Surgical's worldwide procedures during the second quarter of 2026. The data indicates that worldwide procedures grew by 16 percent year over year, with specific gains for Da Vinci procedures rising nearly 15 percent and Ion procedures surging almost 36 percent.
Financial performance metrics cited in the report include a second-quarter revenue of USD 2.89 billion. Based on these strong operational results, Zacks assigned Intuitive Surgical a No. 2 Buy rank, signaling positive analyst sentiment regarding the company's market position and growth trajectory in the surgical robotics sector.
๐ ISRG stock gained 0.02% at EUR 378.93 on Oct 10, 2026.
๐ Worldwide procedures grew 16% year over year in Q2 2026.
๐ฌ Ion procedures surged 36%, while Da Vinci procedures rose 15%.
๐ฐ ISRG reported robust Q2 revenue of USD 2.89 billion.
๐ Zacks upgraded ISRG to No. 2 Buy rank on strong data.
๐ Intuitive Surgical stock traded at EUR 378.93 on October 10, 2026, showing a slight 0.02 percent gain over the previous close.
๐ Worldwide procedures for Intuitive Surgical grew 16 percent year over year in the second quarter of 2026 according to Zacks Research.
๐ฌ Ion procedures specifically saw nearly 36 percent growth, while Da Vinci procedures rose almost 15 percent during the same period.
๐ฐ The company reported a robust second-quarter revenue of USD 2.89 billion.
๐ Zacks assigned Intuitive Surgical a No. 2 Buy rank following the release of its strong quarterly performance data.
๐ The next Xetra trading session for Intuitive Surgical is scheduled to open on October 12, 2026.
Bullish Signals
Worldwide procedures grew 16% in Q2 2026.
Ion procedures rose nearly 36% with new tech.
Da Vinci procedures up 15%, reinforcing dominance.
Q2 revenue reached USD 2.89 billion.
Zacks upgraded to No. 2 Buy rank.
Bullish Signals
Worldwide procedures grew 16 percent year over year in the second quarter of 2026, demonstrating strong demand for the company's surgical systems.
Ion procedures experienced nearly 36 percent growth, highlighting successful expansion into new robotic technology segments.
Da Vinci procedures rose almost 15 percent, reinforcing the core business unit's continued market dominance and adoption.
The company achieved a second-quarter revenue of USD 2.89 billion, reflecting solid top-line execution.
Zacks Research upgraded or maintained a positive outlook by assigning Intuitive Surgical a No. 2 Buy rank based on recent financial figures.
Intuitive Surgical (ISRG) reported second-quarter revenue of $2.89 billion and adjusted EPS of $2.80, both beating Wall Street estimates. Despite the financial beat, shares fell 11% as management signaled a deceleration in growth trajectory and announced plans to cut prices on key instrument lines starting in the first half of 2027.
The company's high-margin recurring revenue model, which accounts for roughly 60% of its $10.1 billion fiscal 2025 revenue, faces direct pressure from these planned price reductions. While worldwide da Vinci procedures grew 16% year over year in the quarter, guidance for full-year procedure growth was lowered to approximately 14.5%, reflecting concerns about slowing US adoption and affordability pressures at both provider and patient levels.
Valuation scrutiny remains a primary concern as ISRG trades at roughly 47x trailing earnings, double the average of large-cap device peers like Stryker and Boston Scientific. Analyst consensus is split between 'Moderate Buy' ratings and caution over stretched multiples, with some firms downgrading to 'Hold' citing that the premium valuation requires exceptional performance to justify the slowing growth rate and margin compression risks.
Looking ahead, the stock's recovery depends on either a significant multiple contraction or evidence that volume gains offset price cuts. The da Vinci 5 system ramp and international expansion provide stability, but investors are watching closely for stabilization in procedure growth rates in the upcoming October fiscal Q3 report to validate the company's long-term franchise value.
๐ ISRG beat Q2 estimates with $2.89B revenue and $2.80 adjusted EPS.
๐ Shares fell 11% on guidance for decelerating procedure growth and H1 2027 price cuts.
๐ฐ High-margin instruments, representing 60% of revenue, face direct threat from planned pricing.
๐ฌ Worldwide da Vinci procedures grew 16% YoY despite slowing US growth due to affordability.
๐ Analysts downgraded to 'Hold' citing stretched 47x valuation and margin compression risks.
๐ ISRG delivered Q2 revenue of $2.89 billion and adjusted EPS of $2.80, beating consensus estimates of $2.82 billion and $2.51 respectively.
๐ Shares dropped 11% on the news as management guided for decelerating procedure growth and announced price cuts for instruments starting in H1 2027.
๐ฐ Approximately 60% of ISRG's revenue comes from high-margin instruments and accessories, which are directly threatened by the planned pricing strategy.
๐ The company trades at roughly 47x trailing earnings, significantly higher than peers like Stryker (28.5x) and Boston Scientific (16.6x).
๐ฌ Worldwide da Vinci procedures grew 16% year over year in the June quarter, though US growth is decelerating due to affordability pressures.
๐ ๏ธ The da Vinci 5 system ramp continues with 246 of 468 systems placed in the quarter being the newer generation model.
๐ International placement and new FDA clearances for mitral-valve repair are expanding the addressable market for the company.
๐ Analyst consensus is a 'Moderate Buy' but recent actions include downgrades to 'Hold' due to concerns over stretched valuations and margin compression.
๐ฏ The recurring revenue model relies on procedure volume, which could be negatively impacted if price cuts fail to stimulate demand sufficiently.
๐ฎ Investors are awaiting the October 20 fiscal Q3 report for signs that procedure growth has stabilized or that volume offsets price reductions.
Bullish Signals
Beat Q2 revenue and EPS estimates.
Worldwide da Vinci procedures grew 16% YoY.
Ramping da Vinci 5; 246 of 468 placed.
New FDA clearance opens 160k annual procedure opportunity.
International expansion diversifies revenue streams.
Intuitive Surgical (ISRG) remains a primary focus for investors following Barclays' initiation of coverage ahead of its October 20 earnings update. The company's investment narrative hinges on the continued compounding of robotic-assisted procedures within its installed base, specifically the da Vinci and Ion systems. Key metrics under scrutiny include procedure trends, system utilization rates, and margin durability as hospitals navigate tight budgets in regions like China and Europe.
The article highlights a significant competitive risk: the entry of Johnson & Johnson's OTTAVA platform into the market. Analysts are weighing this new competition against ISRG's strong historical performance, noting that Q2 2026 data showed 16% worldwide procedure growth with rising international usage reaching 38% of da Vinci volume. This recurring revenue stream from instruments and accessories is viewed as more critical than single-quarter system placements.
Consensus financial models project ISRG revenue growing at 11.9% annually over the next three years, with profit margins expected to expand from 28.4% to 30.7%. Under this framework, earnings are forecasted to rise from US$3.1 billion today to approximately US$4.8 billion by 2029. However, the current P/E multiple of 44.3x is noted as being significantly higher than the broader medical equipment sector average of 24.8x, suggesting high valuation expectations tied to the durability of its recurring revenue model.
Optimistic analyst views project even higher growth, estimating US$17.4 billion in revenue and US$5.1 billion in earnings by 2029, though these forecasts may shift given recent commentary from Jim Cramer regarding valuation and the competitive threat from J&J. The stock's fair value is currently implied to have a 15% potential upside, although this discount could narrow quickly as fresh information on competition and utilization lands.
๐ Intuitive Surgical faces scrutiny ahead of October 20 earnings update following Barclays' initiation.
โ๏ธ Primary competitive risk involves Johnson & Johnson's OTTAVA platform entering robotic surgery market.
๐ Q2 data revealed 16% worldwide procedure growth and rising international usage to 38%.
๐ฐ Analysts project revenue growing at 11.9% annually with margins expanding from 28.4% to 30.7%.
๐ Optimistic views project revenue reaching US$17.4 billion and earnings hitting US$5.1 billion by 2029.
๐ Intuitive Surgical faces scrutiny ahead of its October 20 earnings update following Barclays' initiation of coverage.
โ๏ธ The primary competitive risk involves Johnson & Johnson's newly authorized OTTAVA platform entering the robotic surgery market.
๐ Q2 2026 data revealed 16% worldwide procedure growth and rising international usage to 38% of da Vinci volume.
๐ฐ Analyst consensus models project revenue growing at 11.9% annually with profit margins expanding from 28.4% to 30.7% over three years.
๐ Earnings are forecasted to increase from US$3.1 billion today to approximately US$4.8 billion by 2029 under standard models.
๐ต The current P/E multiple of 44.3x is significantly higher than the broader medical equipment sector average of 24.8x.
๐ Optimistic analyst views project revenue reaching US$17.4 billion and earnings hitting US$5.1 billion by 2029.
๐ Jim Cramer's recent comments on valuation have kept attention on investor willingness to pay for the company's growth story.
๐ Recurring revenue from instruments, accessories, and service is viewed as more critical than single-quarter system placements.
๐ Rising usage outside the US supports the business model even if pricing pressure or slower system decisions emerge.
Bullish Signals
Q2 2026 procedure growth hit 16% globally.
International da Vinci usage reached 38% of volume.
Margins projected to expand from 28.4% to 30.7%.
Recurring revenue from instruments ensures stability.
Revenue forecasted at US$17.4B and earnings at US$5.1B by 2029.
International usage of da Vinci systems has risen to 38% of total volume, diversifying revenue streams beyond the US market.
Analyst consensus projects a durable margin expansion trajectory from 28.4% today to 30.7% over the next three years.
The company's recurring revenue model driven by instruments and accessories provides stability independent of system sales cycles.
Optimistic analyst forecasts suggest potential for US$17.4 billion in revenue and US$5.1 billion in earnings by 2029.
Risk Factors
The launch of Johnson & Johnson's OTTAVA platform introduces a direct competitive threat to Intuitive Surgical's high-margin robotic franchise.
The current P/E multiple of 44.3x is substantially higher than the 24.8x average for the broader US medical equipment group, indicating high valuation expectations.
Recent commentary from Jim Cramer highlights concerns regarding whether investors are willing to pay a premium for the company's growth story.
Intuitive Surgical (ISRG) shares rose 1.73% to $411.78 on October 7, 2026, following a Zacks Rank No. 2 Buy rating assigned on October 6. The medical device giant reported robust second-quarter revenue of $2.89 billion, representing an 18.4% year-over-year increase driven by growth in worldwide procedures.
Analyst consensus remains bullish with Investing.com citing a Buy rating from 32 analysts and an average 12-month price target of $477.21, implying approximately 15.9% upside from current levels. The high target reaches $685.00 while the low sits at $324.00, reflecting divergent expectations within the sector.
Company fundamentals highlight a strong operational trajectory with worldwide procedures expanding 16% year over year in Q2 2026. This growth supports recurring demand for its da Vinci surgical systems and Ion endoluminal system, positioning the company well ahead of its next earnings release scheduled for October 20, 2026.
The stock currently trades at a market capitalization of $145.5 billion, sitting 31.81% below its 52-week high of $603.88. Investors are watching to see if the reported revenue expansion and procedure growth can bridge the valuation gap before the upcoming quarterly report.
๐ ISRG stock rose 1.73% to $411.78 after Zacks Buy rank upgrade.
๐ฐ Q2 revenue hit $2.89 billion, up 18.4% year-over-year on procedure growth.
๐ฌ Worldwide procedures grew 16% in Q2, boosting da Vinci and Ion demand.
๐ฏ Analysts rate ISRG a Buy with a $477.21 price target (15.89% upside).
๐ Q3 earnings release scheduled for October 20, 2026.
๐ Intuitive Surgical stock gained 1.73% to trade at $411.78 on October 7, 2026, following a Zacks Buy rank upgrade.
๐ฐ Second-quarter revenue reached $2.89 billion, marking an 18.4% year-over-year increase driven by procedure volume growth.
๐ฌ Worldwide procedures grew 16% year over year in Q2 2026, reinforcing demand for the da Vinci and Ion surgical systems.
๐ฏ Analyst consensus shows a Buy rating with an average 12-month price target of $477.21, suggesting 15.89% upside potential.
๐ The company is scheduled to release Q3 earnings on October 20, 2026, providing the next major data checkpoint.
๐ Intuitive Surgical holds a market capitalization of $145.5 billion with a 52-week trading range between $328.57 and $603.88.
Bullish Signals
Revenue grew 18.4% YoY to $2.89B in Q2.
Worldwide procedures rose 16% validating recurring revenue.
Analysts see 15.89% upside with $477.21 target.
Zacks Rank No. 2 Buy reflects positive sentiment.
Risk Factors
Shares trade 31.81% below 52-week high of $603.88.
Intuitive Surgical reported second-quarter revenue of $2.89 billion, a significant 18.4% year-over-year increase driven by strong procedure volume.
Worldwide procedures grew 16% year over year in Q2 2026, validating the recurring revenue model for its da Vinci and Ion surgical systems.
Analyst consensus from Investing.com includes a Buy rating with an average 12-month price target of $477.21, indicating 15.89% upside from current levels.
The stock received a Zacks Rank No. 2 Buy classification on October 6, 2026, reflecting positive sentiment regarding the medical-instruments industry outlook.
Risk Factors
Intuitive Surgical shares are trading 31.81% below their 52-week high of $603.88, suggesting a potential valuation gap despite recent revenue growth.
The stock price remains well below analyst expectations as the market awaits confirmation that Q3 results will sustain the current growth trajectory.
Intuitive Surgical (ISRG) has underperformed the broader market over the past year, losing 8.2% compared to the S&P 500's 17.1% gain. The article analyzes the specific business drivers required for ISRG stock to recover and grow significantly over a three-year horizon. It posits that substantial revenue growth from its core Instruments and Accessories segment is the primary engine needed, supported by a potential recovery in valuation multiples.
The analysis highlights that Intuitive's largest revenue source, the Instruments and Accessories segment, generated $6.0 billion of its $10.1 billion fiscal 2025 revenue. The scenario assumes annual revenue growth of 17.6% over three years, which would drive approximately 83% of the projected stock gain. This growth is contingent on hospitals continuing to adopt newer da Vinci systems and increasing the volume of procedures performed.
However, the outlook faces headwinds including management's guidance for moderated US procedure growth and a planned price reduction on certain instruments starting in the first half of 2027. The article notes that while revenue remains the main source of potential upside, valuation multiple compression poses significant downside risk to total returns if market sentiment does not improve.
Intuitive Surgical reported a 16% increase in total procedures during fiscal Q2 2026, with the newer da Vinci 5 system accounting for the majority of new placements. Despite this operational strength, the company's ability to sustain high growth depends on overcoming the slowdown in elective procedures and maintaining margins despite pricing adjustments.
๐ ISRG stock declined 8.2% over the past twelve months vs S&P 500's 17.1%.
Medical device launchRegulatory approvalAI-generated analysis
Intuitive Surgical (ISRG) has secured fresh European clearances for its da Vinci robotic-surgery platform, significantly expanding its clinical reach in the region. Notably, the company obtained a CE mark allowing its single-port system to be used in transvaginal gynecologic procedures, marking a first-of-its-kind indication for this specific configuration.
In addition to the gynecological breakthrough, Intuitive Surgical advanced its newer flagship platform with a clearance for cardiac surgery applications. This development reinforces the company's strategic ambition to extend robotic surgery into specialized fields where adoption has historically been lower, thereby broadening the total addressable market for its systems in Europe.
The article highlights that these clearances are expected to drive growth in procedure volumes as hospitals adopt the expanded capabilities of the da Vinci family. With a quarterly update approaching later in the month, investors will closely monitor procedure trends and the deployment of the new flagship generation, which features refinements in imaging and instrument control designed to aid surgeons.
Intuitive Surgical's business model relies on a growing installed base of systems that generate recurring revenue through ongoing use. As the company widens cleared indications and rivals advance their own robotic systems, Intuitive Surgical's strong clinical evidence and steady research commitments are positioned to support continued adoption and market expansion.
๐ช๐บ ISRG secured CE mark for da Vinci single-port gynecologic procedures in Europe.
๐ฌ European clearance granted for flagship platform use in cardiac surgery procedures.
๐ Quarterly update scheduled in October to track procedure volume and system spread.
๐ค da Vinci platform enables minimally invasive urology, gynecology, and general surgery globally.
๐ฐ Recurring revenue grows via expanding installed base and increasing procedure volumes.
๐ช๐บ ISRG secured a CE mark in Europe for its da Vinci single-port system to perform transvaginal gynecologic procedures, a first-of-its-kind indication.
๐ฌ The company received clearance for its newer flagship platform to be used in cardiac surgery procedures within the European market.
๐ A quarterly update is scheduled later in October, with procedure volume trends and the spread of the new flagship system as key focus points.
๐ค ISRG's da Vinci platform continues to define the surgical-robotics sector by enabling minimally invasive procedures through small incisions across urology, gynecology, and general surgery.
๐ฅ The single-port version allows operations through a single small opening, specifically suited for confined spaces and expanding the system's role within the da Vinci family.
๐ฐ Intuitive Surgical's recurring revenue model is driven by an expanding installed base of systems and the increasing number of procedures performed on them.
๐ The surgical-robotics field faces growing competition from large medical-device makers and new entrants, focusing on system capability and cost efficiency.
๐ Strong clinical evidence remains central to Intuitive Surgical's strategy, supporting fresh clearances and encouraging wider adoption of its platform.
Bullish Signals
Europe CE mark for da Vinci single-port gynecologic procedures.
Cardiac surgery clearance expands European robotic platform applications.
Fresh clearances drive procedure volume growth via installed base.
Bullish Signals
ISRG secured a CE mark in Europe for its da Vinci single-port system to perform transvaginal gynecologic procedures, marking a first-of-its-kind indication that widens the range of operations the platform can address.
The company advanced its newer flagship platform with a clearance for cardiac surgery applications in Europe, reflecting broadening ambitions to extend robotic surgery into less established fields.
ISRG's business model relies on a growing installed base of systems and recurring use, where fresh clearances are expected to drive growth in procedure volumes as hospitals adopt the expanded capabilities.
Intuitive Surgical (ISRG) shares fell 2.32% to close at $391.95 on October 2, 2026, despite reporting strong Q2 results that significantly outperformed the prior year. The company posted revenue of $2.89 billion, an 18.4% increase from $2.44 billion in the same quarter of 2025, while net profit rose to $818.1 million from $658.4 million.
Analyst sentiment remains bullish with RBC Capital maintaining a Buy rating and setting a $575 price target, which stands $183 above the current closing price. However, market attention is focused on whether the company can sustain its growth trajectory into the second half of 2026, particularly given recent deceleration in domestic procedure growth.
Domestic da Vinci procedure growth slowed to 12% in Q2 2026 compared to 14% in the previous quarter, though international expansion continues to drive momentum with a robust 20% growth rate. Management has maintained its full-year guidance for procedure growth between 13.5% and 15.5%, keeping valuation and execution capabilities central to investor debate ahead of the October 20 earnings report.
๐ ISRG stock closed down 2.32% at $391.95 despite strong Q2 performance.
๐ฐ Q2 revenue surged 18.4% YoY to $2.89 billion with $818.1M net profit.
๐ International procedure growth hit 20%, offsetting domestic da Vinci slowdown to 12%.
Intuitive Surgical (ISRG) maintains a dominant position in robotic surgery with its da Vinci system, which has achieved an installed base of 11,710 units by mid-2026. Approximately 86% of the company's revenue is recurring, derived from instruments, accessories, and services tied to each procedure, providing a steady earnings stream as global procedures grow around 14%. The high switching costs associated with surgeon training and specialized instrument requirements reinforce its market moat.
Despite a recent stock decline of roughly 35% to approximately $395, Intuitive Surgical trades at a premium valuation of 46 times earnings. Bulls argue that the company's recurring revenue model, long procedure runway, and the newer da Vinci 5 systemโwhich drives usage 11% higher than older modelsโsupport continued growth. Additionally, increased market adoption driven by competitors could expand the total addressable market for Intuitive.
Bearish concerns focus on emerging competition from Medtronic's Hugo and Johnson & Johnson's Ottava systems, which have received US regulatory clearance. These rivals target hospital networks with space-saving designs that directly challenge Intuitive's core customer base. The market appears to be pricing in competitive risks, as any slowdown in system placements or pricing pressure could lead to further valuation compression at current multiples.
๐ Installed base reaches 11,710 systems by mid-2026 with 12% YoY growth.
๐ฐ ~86% of revenue is recurring from instruments and services tied to procedures.
๐ง Newer da Vinci 5 drives utilization 11% higher than older systems.
โ ๏ธ Medtronic's Hugo and J&J's Ottava received US regulatory clearance, introducing competition.
๐ Stock fell ~35% to $395 as market prices in competitive risks.
๐ Intuitive Surgical has an installed base of 11,710 da Vinci systems by mid-2026, representing a 12% year-over-year increase.
๐ฐ Approximately 86% of ISRG's revenue is recurring from instruments and services tied to each surgical procedure.
๐ Global procedures for Intuitive Surgical are growing at a rate of around 14% annually.
๐ง The newer da Vinci 5 system is driving utilization approximately 11% above that of older systems.
โ ๏ธ Medtronic's Hugo and Johnson & Johnson's Ottava have received US regulatory clearance, introducing direct competition.
๐ฅ Competitors like Ottava utilize space-saving designs specifically targeting hospital networks reliant on Intuitive.
๐ธ ISRG trades at 46 times earnings, implying high expectations for continued double-digit procedure growth.
๐ The stock has fallen about 35% from its highs to roughly $395 as the market prices in competitive risks.
๐ฅ 100 hedge funds held Intuitive Surgical at the end of Q2 2026, down slightly from 103 the previous quarter.
๐ Multi-million-dollar capital placements for ISRG remain sensitive to hospital budget constraints and borrowing costs.
Bullish Signals
Recurring revenue from instruments/services accounts for ~86% of total revenue.
Risk Factors
Medtronic/J&J systems threaten Intuitive's market share.
Valuation at 46x earnings risks compression on slowdowns.
Capital placements face pressure from hospital budgets.
Rising borrowing costs impact multi-million dollar deals.
Bullish Signals
Intuitive Surgical benefits from a recurring revenue model where approximately 86% of revenue comes from instruments and services tied to procedures.
The company has expanded its installed base to 11,710 da Vinci systems by mid-2026, up 12% in a year.
Global procedure volumes are growing around 14%, providing a long runway for revenue expansion.
The newer da Vinci 5 system is driving higher usage with utilization running about 11% above the older system.
High switching costs due to surgeon training and specialized instruments create a durable competitive advantage.
Risk Factors
Intuitive Surgical faces heavy competition for the first time from Medtronic's Hugo and Johnson & Johnson's Ottava systems.
New entrants with space-saving designs like Ottava target hospitals that rely on Intuitive, potentially pressuring system placements.
The stock trades at 46 times earnings, meaning any slowdown in placements or pricing could prompt significant valuation compression.
Multi-million-dollar capital placements remain sensitive to hospital budget constraints and rising borrowing costs.
Intuitive Surgical (ISRG) maintains its position as the market leader in its healthcare peer group, demonstrating superior growth and profitability metrics compared to five major rivals. The company trades at a premium valuation of 45.3 times trailing earnings, significantly higher than competitors like Globus Medical which trades at 18.8x, even after ISRG's stock declined over 10% in the past year. Intuitive achieves this premium by generating higher operating margins and faster revenue growth than any rival in the group.
The company's business model relies heavily on recurring revenue from instruments sold for use with its installed da Vinci surgical systems. As of fiscal Q2 2026, ISRG had nearly 13,000 systems installed globally, contributing to a 16% quarter-over-quarter increase in total procedures. Approximately 85% of the company's revenue is classified as recurring, driven by the high volume of procedures performed on existing hardware.
Despite its strong historical performance, Intuitive faces potential headwinds including slowing growth in the U.S. market and upcoming product changes. Management forecasts da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026, but acknowledges that U.S. growth has decelerated, partly due to patient insurance coverage changes. Additionally, the company plans to launch longer-lasting instruments in the first half of 2027, which will reduce the cost per use for customers and could impact future revenue streams.
๐ ISRG leads peers with faster growth and higher operating margins.
๐ฐ Stock trades at 45.3x earnings, double rival Globus Medical valuation.
๐ง ~85% of revenue is recurring from installed da Vinci instrument sales.
๐ Total procedures grew 16% in Q2 2026 across 13,000 systems.
โ ๏ธ Longer-lasting instruments launching H1 2027 will lower customer cost per use.
๐ Intuitive Surgical leads its healthcare peer group with faster growth and higher operating margins than all five rivals.
๐ฐ The stock trades at a premium 45.3x trailing earnings, more than double the valuation of rival Globus Medical.
๐ง Approximately 85% of ISRG's revenue is recurring, driven by instrument sales for installed da Vinci systems.
๐ Total procedures grew 16% in fiscal Q2 2026 across nearly 13,000 installed systems worldwide.
๐บ๐ธ U.S. procedure growth has slowed, with management citing changes in patient insurance coverage as a factor.
๐ฏ Management forecasts da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026.
โ ๏ธ The company plans to launch longer-lasting instruments in H1 2027, which will lower the cost per use for customers.
๐ A da Vinci procedure growth rate below 13.5% would indicate a slowdown faster than management expects.
Bullish Signals
Beats rivals with faster growth and higher margins.
Risk Factors
U.S. procedure growth slowed as patients defer elective surgeries.
Growth below 13.5% in 2026 implies slower-than-expected pace.
New instruments in H1 2027 may lower revenue per use.
Bullish Signals
Intuitive Surgical grows faster and earns higher operating margins than any of its five healthcare rivals.
The company holds the highest P/E ratio in its peer group at 45.3x, reflecting strong investor confidence despite a recent stock decline.
ISRG generated $6.0 billion in revenue from Instruments and Accessories in fiscal 2025, accounting for the majority of total revenue.
Total procedures grew 16% in fiscal Q2 2026, demonstrating strong demand for its installed da Vinci systems.
Risk Factors
U.S. procedure growth has already slowed, driven by patients deferring elective procedures due to insurance coverage changes.
Management warns that if da Vinci procedure growth falls below 13.5% in 2026, the company is slowing faster than expected.
The upcoming launch of longer-lasting instruments in H1 2027 will reduce the cost per use for customers, potentially impacting revenue per procedure.
Wall Street Zen has downgraded Intuitive Surgical (ISRG) stock from a Buy rating to a Hold, citing a wide valuation range despite the company's expanding operating picture. This analyst sentiment shift reflects market caution regarding the stock price relative to its one-year highs, even as broader consensus remains broadly constructive with 22 analysts maintaining Buy ratings against eight Holds and one Sell.
Intuitive Surgical reported robust second-quarter revenue growth of 18.40 percent year over year, generating USD 2.89 billion in sales. This strong momentum serves as a counterweight to the more cautious analyst downgrades, suggesting that while the stock valuation is being reassessed, the underlying business fundamentals and sales velocity remain measurable and positive.
The company's market capitalization stands at USD 142.2 billion as of October 1, 2026, with shares trading around EUR 359.95 on European exchanges. Investors are now focused on the upcoming third-quarter earnings report scheduled for October 20, 2026, which will serve as a critical checkpoint to determine if the second-quarter growth rate can be sustained.
๐ Wall Street Zen downgrades ISRG to Hold citing valuation concerns.
๐ฐ Q2 revenue surged 18.4% YoY to USD 2.89 billion.
๐ Market cap stands at USD 142.2 billion as of Oct 1, 2026.
๐ฏ Analyst consensus target price is USD 508.68 per share.
๐ Q3 earnings report expected on October 20, 2026.
๐ Wall Street Zen downgrades Intuitive Surgical stock from Buy to Hold due to valuation concerns despite strong fundamentals.
๐ฐ Second-quarter revenue surged 18.40 percent year over year to reach USD 2.89 billion, demonstrating continued sales momentum.
๐ Market capitalization is valued at USD 142.2 billion with shares trading near EUR 359.95 on October 1, 2026.
๐ฏ Analyst consensus target price sits at USD 508.68, though JPMorgan recently cut its specific target to USD 450.00.
๐ The next key data point is the third-quarter earnings report expected on October 20, 2026.
๐ฅ Intuitive Surgical operates in the Healthcare sector as a leader in medical instruments and surgical robotics.
Risk Factors
Wall Street Zen downgraded stock from Buy to Hold.
JPMorgan cut price target from $550 to $450.
Stock remains below one-year high of $603.88.
Bullish Signals
Intuitive Surgical achieved an 18.40 percent year-over-year revenue increase in the second quarter, generating USD 2.89 billion in sales.
The company maintains a substantial market capitalization of USD 142.2 billion, indicating strong investor confidence in its long-term position.
A majority of analysts (22 out of 31) still rate the stock as a Buy, suggesting broad institutional support despite the downgrade.
Risk Factors
Wall Street Zen downgraded the stock from Buy to Hold, signaling concerns that the current valuation is stretched relative to recent highs.
JPMorgan cut its price target from USD 550.00 to USD 450.00 in July, reflecting a more bearish view on near-term upside potential.
The stock remains below its one-year high of USD 603.88, indicating that the market has not yet fully priced in the recent growth.
Intuitive Surgical (ISRG) shares are trading at EUR 364.08 in pre-market activity, representing a 0.69% gain against the previous closing price of EUR 361.60. This movement occurred on September 30, 2026, with specific bid and ask prices reported by Lang & Schwarz.
The upward momentum is directly linked to recent regulatory developments in Europe. Yahoo Finance reported that Intuitive Surgical received CE mark approval for its da Vinci SP single-port robotic system specifically for use in transvaginal gynecologic procedures.
This European approval expands the supported indications for the da Vinci SP system within the region, marking a significant step in broadening the device's clinical utility and potential market reach in Europe.
๐ ISRG stock rises 0.69% to EUR 364.08 in pre-market trading.
โ da Vinci SP receives CE mark for transvaginal gynecologic procedures.
๐ Regulatory win expands clinical indications and market potential in Europe.
๐ Intuitive Surgical stock is up 0.69% to EUR 364.08 in pre-market trading on September 30, 2026.
โ The company received CE mark approval for the da Vinci SP system for transvaginal gynecologic procedures in Europe.
๐ This regulatory win expands the clinical indications and market potential of the da Vinci SP robotic system within the European region.
๐ฐ Pre-market bid and ask prices were reported at EUR 362.30 and EUR 365.85 respectively by Lang & Schwarz.
Bullish Signals
Shares gained 0.69% on new European approval.
Secured CE mark for da Vinci SP system.
Regulatory expansion broadens European market utility.
Bullish Signals
Intuitive Surgical shares gained 0.69% in pre-market trading following the announcement of a new European regulatory approval.
The company secured CE mark approval for its da Vinci SP single-port robotic system to be used in transvaginal gynecologic procedures.
This regulatory expansion broadens the clinical utility and potential addressable market for the da Vinci SP system within Europe.
Intuitive Surgical, Inc. (ISRG) has been a trending stock, outperforming the broader market with shares rising 10.1% over the past month compared to the S&P 500's 1% gain. The company recently reported quarterly revenues of $2.89 billion, beating the consensus estimate of $2.81 billion by 3.08%, while EPS of $2.8 exceeded expectations by 12.9%. This performance marks the fourth consecutive quarter where ISRG beat earnings estimates and the third time topping revenue forecasts in the trailing four quarters.
Analysts maintain a strong outlook for Intuitive Surgical, with consensus earnings projections showing significant growth. For the current quarter, expected EPS is $2.61, representing an 8.8% increase year-over-year. Full-year consensus estimates stand at $10.74 (up 20.3%), while the next fiscal year projects $11.98 in earnings (an 11.6% rise). Revenue growth is also robust, with full-year and next-year sales estimates of $11.74 billion and $13.21 billion respectively, indicating sustained expansion.
Despite its strong operational performance and a Zacks Rank #2 (Buy) rating suggesting near-term outperformance, Intuitive Surgical faces valuation concerns. The company is graded an F on the Zacks Value Style Score, indicating it trades at a premium relative to its peers based on traditional metrics like P/E and P/S ratios. While the high valuation suggests the market prices in significant growth potential, the stock's fair value remains tied to future earnings revisions and sustained revenue expansion.
๐ ISRG shares rose 10.1% last month, outperforming S&P 500 by 9.1%.
๐ฐ Quarterly revenue hit $2.89B, beating estimates by 3.08%.
๐ EPS beat expectations by 12.9%, marking fourth consecutive quarter of beats.
๐ญ Analysts project current quarter EPS of $2.61, an 8.8% year-over-year increase.
โ ๏ธ Stock trades at a premium to peers with a Zacks Value Style Score of F.
๐ ISRG shares gained 10.1% over the past month, significantly outperforming the S&P 500 composite which rose only 1%.
๐ฐ The company reported quarterly revenues of $2.89 billion, surpassing analyst consensus estimates by 3.08%.
๐ Intuitive Surgical beat EPS expectations by 12.9% in the last quarter, marking a fourth consecutive quarter of earnings beats.
๐ญ Analysts project current quarter EPS of $2.61, reflecting an 8.8% year-over-year increase.
๐ Full-year consensus earnings estimates for ISRG are set at $10.74, indicating a 20.3% growth from the prior year.
๐ผ Revenue guidance remains strong with full-year sales estimates of $11.74 billion and next-year projections of $13.21 billion.
๐ The stock holds a Zacks Rank #2 (Buy) based on positive trends in earnings estimate revisions.
โ ๏ธ ISRG is graded an F on the Zacks Value Style Score, signaling it trades at a premium to its peers.
Bullish Signals
Shares rose 10.1% last month, beating S&P 500.
Risk Factors
Graded F on Zacks Value Style Score due to premium valuation.
High valuation risks sensitivity to earnings or revenue slowdowns.
Bullish Signals
Shares returned +10.1% over the past month, significantly outperforming the S&P 500 composite's +1% gain.
The company beat consensus EPS estimates by +12.9% and revenue estimates by +3.08% in the last reported quarter.
Intuitive Surgical has beaten earnings estimates for four consecutive trailing quarters and topped revenue estimates three times during that period.
Analysts project current quarter EPS of $2.61, representing an 8.8% increase from the year-ago quarter.
Full-year consensus earnings estimate of $10.74 points to a +20.3% change from the prior year.
Revenue estimates for the current and next fiscal years are $11.74 billion and $13.21 billion, indicating +16.7% and +12.5% growth respectively.
The stock is assigned a Zacks Rank #2 (Buy), suggesting it may outperform the broader market in the near term.
Risk Factors
Intuitive Surgical is graded an F on the Zacks Value Style Score, indicating it is trading at a premium to its peers based on valuation multiples.
The high valuation suggests the stock price may be sensitive to any slowdown in future earnings growth or revenue expansion.
Intuitive Surgical (NASDAQ:ISRG) reported strong fiscal Q2 results with revenue increasing 19% year-over-year to $2.89 billion, driven by a 15% rise in worldwide da Vinci procedure volumes. The company's recurring revenue model proved resilient as instruments and accessories revenue grew 18% to $1.73 billion, reflecting the compounding value of its expanding installed base which reached 11,710 systems.
Management provided forward-looking guidance expecting procedure growth between 13.5% and 15.5% for fiscal 2026, with a target to land near the midpoint of that range. However, Intuitive faces margin headwinds from tariffs, anticipating a non-GAAP gross margin decline to 68-69% in 2026 due to an estimated one-percentage-point tariff impact, with warnings that additional tariffs could materially affect results.
The article contrasts Intuitive's growth trajectory against Gilead Sciences, noting that while Intuitive relies on sustaining its high-growth engine amidst cost pressures, Gilead faces portfolio concentration risks despite strong HIV franchise performance. Analysts highlight the strategic divergence where Intuitive must maintain mid-teens procedure growth rates as the business scales, whereas Gilead seeks diversification beyond its dominant HIV segment.
Intuitive Surgical placed 468 da Vinci systems in the quarter, including 246 units of the newer da Vinci 5 model. The company's non-GAAP EPS reached $2.80 compared to $2.19 a year earlier, demonstrating profitability growth alongside revenue expansion. Investors are weighing the risk-adjusted upside of Intuitive's established growth machine against the potential for continued high-level execution required to sustain its market position.
๐ ISRG Q2 revenue grew 19% YoY to $2.89B driven by da Vinci volume increases.
๐ง Instruments revenue rose 18% to $1.73B validating recurring model on 11,710 systems.
๐ Management forecasts 13.5%-15.5% procedure growth for fiscal 2026 near midpoint target.
โ ๏ธ Non-GAAP margins expected to fall to 68-69% in 2026 due to tariff costs.
๐ฐ Non-GAAP EPS reached $2.80, up from $2.19 a year earlier in Q2.
๐ Intuitive Surgical reported fiscal Q2 revenue growth of 19% year-over-year, reaching $2.89 billion driven by a 15% increase in worldwide da Vinci procedure volumes.
๐ง Instruments and accessories revenue increased 18% to $1.73 billion, validating the company's recurring revenue model based on its expanding installed base of 11,710 systems.
๐ Management expects worldwide da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026, targeting a result near the midpoint of that range.
โ ๏ธ The company anticipates non-GAAP gross margins falling to 68-69% in 2026 due to an estimated one-percentage-point tariff impact on costs.
๐ญ Intuitive placed 468 da Vinci systems during the quarter, with 246 units being the newer da Vinci 5 model, contributing to a 12% increase in the global installed base.
๐ฐ Non-GAAP EPS reached $2.80 in fiscal Q2, representing significant growth compared to $2.19 reported a year earlier.
๐ Cell Therapy sales declined 14% to $417 million amid competitive headwinds, though this segment is less central to Intuitive's core robotics business than Gilead's HIV focus.
๐ค The da Vinci installed base continues to compound value, as more systems support additional procedures which in turn drive demand for consumables and services.
๐ Management cautioned that tariffs beyond current assumptions could materially affect 2026 financial results, introducing external cost risks to the growth trajectory.
Bullish Signals
Revenue grew 19% YoY driven by expanding procedure volumes.
Risk Factors
Non-GAAP gross margins expected to decline to 68-69% in fiscal 2026.
Additional tariffs could materially affect 2026 financial results.
Worldwide da Vinci procedure growth slowed to 15% in Q2.
Bullish Signals
Intuitive Surgical achieved a 19% year-over-year revenue increase in fiscal Q2, demonstrating robust top-line growth driven by expanding procedure volumes.
The company successfully placed 468 da Vinci systems in the quarter, growing its global installed base to 11,710 units and reinforcing its recurring revenue model.
Non-GAAP EPS grew significantly to $2.80 from $2.19 a year earlier, indicating strong profitability alongside revenue expansion.
Instruments and accessories revenue rose 18% to $1.73 billion, confirming the compounding value of the installed base as procedures increase.
Management raised expectations for procedure growth in fiscal 2026, targeting a range of 13.5% to 15.5% with a specific aim to hit the midpoint.
Risk Factors
The company expects non-GAAP gross margins to decline to 68-69% in fiscal 2026 due to an estimated one-percentage-point impact from tariffs.
Management explicitly warned that additional tariffs beyond current assumptions could materially affect the company's 2026 financial results.
Worldwide da Vinci procedure growth slowed slightly to approximately 15% in fiscal Q2 compared to 17% a year earlier, indicating potential deceleration as the business scales.
Intuitive Surgical reported robust financial performance for the second quarter of 2026, generating USD 2.89 billion in revenue. This figure represents an 18.5 percent increase compared to the same period in the prior year and exceeded analyst estimates by 2.6 percent, indicating strong commercial execution despite a measured market reaction.
Operating efficiency improved sequentially during this period, with operating margins expanding from 31 percent in Q1 2026 to 34 percent in Q2 2026. Diluted earnings per share also saw a slight increase, rising from USD 2.28 to USD 2.29 over the same periods, reflecting the company's ability to maintain profitability while scaling revenue.
Despite the positive fundamental results, Intuitive Surgical's stock price closed at USD 398.30 on September 23, 2026, which was down 0.94 percent for the session and remained 34.05 percent below its 52-week high of USD 603.88. The market capitalization stood at approximately USD 140.7 billion, suggesting that investors are weighing current growth against valuation levels and future procedure volume expectations.
The company continues to focus on recurring revenue streams from instruments and system placements as key drivers for future updates. While a meta-analysis of da Vinci surgery outcomes supports its medical technology positioning, the immediate stock factor remains the commercial growth trajectory demonstrated by the double-digit revenue expansion.
๐ ISRG Q2 2026 revenue hit USD 2.89B, up 18.5% year-over-year.
๐ฏ Company beat estimates by 2.6%, confirming strong commercial growth.
๐ฐ Operating margins expanded sequentially to 34% in Q2 2026.
๐ Diluted EPS rose from USD 2.28 to USD 2.29.
๐ข Market cap stood at USD 140.7B as of Sept 23, 2026.
๐ Intuitive Surgical generated USD 2.89 billion in Q2 2026 revenue, marking an 18.5 percent year-over-year increase.
๐ฏ The company beat analyst estimates by 2.6 percent, reinforcing the strength of its commercial growth story.
๐ฐ Operating margins expanded sequentially to 34 percent in Q2 2026, up from 31 percent in the previous quarter.
๐ Diluted earnings per share rose from USD 2.28 to USD 2.29 between Q1 and Q2 2026.
๐ The stock closed at USD 398.30, trading 34.05 percent below its 52-week high of USD 603.88.
๐ข Intuitive Surgical maintained a market capitalization of approximately USD 140.7 billion as of September 23, 2026.
๐ The company released a meta-analysis on da Vinci surgery outcomes to support its medical technology positioning.
Bullish Signals
Revenue grew 18.5% YoY to $2.89B in Q2 2026.
Beat estimates by 2.6%, exceeding market expectations.
Operating margins rose sequentially to 34% in Q2.
EPS increased from $2.28 to $2.29.
Risk Factors
Stock trades 34.05% below 52-week high.
Shares fell 0.94% on earnings release.
Bullish Signals
Intuitive Surgical delivered USD 2.89 billion in Q2 2026 revenue, representing an impressive 18.5 percent year-over-year growth.
The company beat analyst estimates by 2.6 percent, demonstrating that its financial performance exceeds market expectations.
Operating margins improved sequentially to 34 percent in Q2 2026, indicating enhanced operational efficiency and profitability.
Diluted earnings per share increased from USD 2.28 to USD 2.29, showing consistent profit generation alongside revenue growth.
Risk Factors
The stock price remains significantly undervalued relative to its potential, trading 34.05 percent below its 52-week high despite strong fundamentals.
The market reaction was measured with a 0.94 percent decline on the day of the earnings release, suggesting cautious investor sentiment regarding current valuation levels.
The article highlights a divergence in performance trends between Intuitive Surgical (ISRG) and Abbott Laboratories, noting that while the latter faces challenges, ISRG continues to demonstrate robust financial expansion. Specifically, Intuitive Surgical has achieved a significant revenue growth rate of 45%, indicating strong demand for its surgical robotics platforms and continued market penetration.
Despite this impressive top-line performance and the maintenance of high operating margins which suggest efficient cost management within its core business, the company's stock price has experienced a notable decline of 19%. This disconnect between operational success and share price movement suggests that investors may be pricing in future concerns or comparing ISRG against peers like Abbott who offer different capital return profiles.
A key structural characteristic mentioned is that Intuitive Surgical does not currently pay a dividend. This lack of dividend payout contrasts with some of its competitors and implies that the company retains earnings for reinvestment into growth initiatives, research and development, or share buybacks rather than returning cash directly to shareholders in the form of regular distributions.
๐ ISRG revenue surged 45% on robust surgical robotics demand.
๐ฐ High operating margins show strong pricing power and efficiency.
๐ Stock fell 19%, creating a valuation divergence from fundamentals.
๐ซ No dividend paid; earnings retained for reinvestment instead.
๐ Intuitive Surgical reported strong revenue growth of 45%, reflecting robust demand for its surgical robotics solutions.
๐ฐ The company maintains high operating margins, indicating efficient operational execution and pricing power in its core business.
๐ Despite solid fundamentals, ISRG stock has fallen 19%, creating a divergence between operational performance and market valuation.
๐ซ Intuitive Surgical does not pay a dividend, retaining earnings for reinvestment rather than shareholder cash returns.
Risk Factors
No dividend payout may deter income-focused investors.
Bullish Signals
Intuitive Surgical achieved strong revenue growth of 45%, demonstrating significant top-line expansion in its surgical robotics business.
The company maintains high operating margins, reflecting efficient cost management and strong profitability within its core operations.
Risk Factors
Intuitive Surgical does not pay a dividend, which may be viewed as a negative factor by income-focused investors compared to dividend-paying peers.
As of September 22, 2026, Intuitive Surgical (ISRG) trades at $401.65, with Wall Street analysts maintaining a consensus buy rating and a median price target of $483.00, implying approximately 20.3% upside potential. The company has demonstrated consistent revenue growth that exceeds sector averages, driven by the increasing adoption of its da Vinci surgical systems, which supports higher valuation multiples.
Despite the bullish analyst consensus, insider activity presents a notable cautionary signal, with over $127 million in stock sales recorded recently. This heavy insider selling could indicate a lack of confidence in near-term appreciation or represent strategic divestment by key personnel. Additionally, the competitive landscape is shifting as new entrants and established players develop competing robotic surgical platforms, posing potential long-term challenges to ISRG's market dominance and pricing power.
Long-term simulations suggest significant growth potential but also highlight volatility risks. CleaRank's 10-year Monte Carlo simulation projects a base case price near $631 by 2030 (a 1.6x increase from current levels), while the bear case scenario estimates a decline to around $269. Historical performance data indicates that a $10,000 investment in ISRG since September 2016 would have grown to approximately $50,332, significantly outperforming the S&P 500 benchmark which reached about $35,616 over the same period.
๐ ISRG trades at $401.65 with a median price target of $483.00.
๐ฐ Strong revenue growth driven by da Vinci system adoption.
โ ๏ธ Over $127 million in insider stock sales recorded recently.
๐ฎ Monte Carlo simulations project a base case price of $631 by 2030.
๐ ISRG trades at $401.65 with a Wall Street consensus buy rating and a median price target of $483.00.
๐ฐ The company has consistently delivered strong revenue growth exceeding sector averages due to da Vinci system adoption.
โ ๏ธ Over $127 million in insider stock sales have been recorded, signaling potential lack of confidence or strategic divestment.
๐ค Competing robotic surgical platforms from new and established players threaten ISRG's long-term market dominance.
๐ Historical data shows a $10,000 investment since 2016 grew to $50,332, outperforming the S&P 500 benchmark.
๐ฎ Monte Carlo simulations project a base case price of $631 by 2030 with a bear case downside to $269.
Bullish Signals
Revenue growth exceeds sector averages via da Vinci adoption.
Analysts rate Buy with median target of $483.00.
$10k investment since Sep 2016 worth ~$50,332.
Risk Factors
Insiders sold $127M in stock.
Competitors threaten market dominance.
Bullish Signals
ISRG has consistently delivered strong revenue growth that exceeds sector averages, driven by increasing adoption of its da Vinci surgical systems.
The majority of Wall Street analysts maintain Buy ratings with a median price target of $483.00, indicating confidence in future performance and upside potential.
Historical monthly performance trends show that a $10,000 investment in ISRG since September 2016 would be worth about $50,332 today, significantly outperforming the S&P 500.
Risk Factors
Over $127 million in stock sales by insiders has been recorded, representing heavy insider selling that could indicate a lack of confidence in near-term stock appreciation.
New entrants and established players are developing competing robotic surgical platforms, which could challenge ISRG's market dominance and pricing power over time.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)